Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?

被引：1

作者：

Roever, Leonardo ^{[1
]}

Biondi-Zoccai, Giuseppe ^{[2
,3
]}

Rao, Sunil V. ^{[4
]}

机构：

[1] Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, Brazil

[2] Sapienza Univ, Dept Med Surg Sci & Biotechnol, Rome, Italy

[3] IRCCS Neuromed, Dept Angio Cardio Neurol, Pozzilli, Italy

[4] Duke Clin Res Inst, Durham, NC USA

来源：

CLINICAL THERAPEUTICS | 2017年 / 39卷 / 03期

关键词：

cardiovascular risk; dyslipidemia; lipids; statins; EZETIMIBE; ASSOCIATION; HYPERCHOLESTEROLEMIA; ROSUVASTATIN; TRIAL;

D O I：

10.1016/j.clinthera.2017.01.029

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk. (C) 2017 Elsevier HS Journals, Inc. All rights reserved.

引用

页码：659 / 660

页数：2

共 14 条

[1] Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study [J].

Ballantyne, Christie M. ;

Hoogeveen, Ron C. ;

Raya, Joe L. ;

Cain, Valerie A. ;

Palmer, Mike K. ;

Karlson, Bjorn W. .

ATHEROSCLEROSIS, 2014, 232 (01) :86-93

[2]

Fernicr M., 2016, ATHEROSCLEROSIS, V244, P138

[3]

Ferreira AM, 2016, AM J CARDIOVASC DRUG

[4] Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe) [J].

Kim, Kyung-Jin ;

Kim, Sang-Hyun ;

Yoon, Young Won ;

Rha, Seung-Woon ;

Hong, Soon-Jun ;

Kwak, Choong-Hwan ;

Kim, Weon ;

Nam, Chang-Wook ;

Rhee, Moo-Yong ;

Park, Tae-Ho ;

Hong, Taek-Jong ;

Park, Sungha ;

Ahn, Youngkeun ;

Lee, Namho ;

Jeon, Hui-Kyung ;

Jeon, Dong-Woon ;

Han, Kyoo-Rok ;

Moon, Keon-Woong ;

Chae, In-Ho ;

Kim, Hyo-soo .

CARDIOVASCULAR THERAPEUTICS, 2016, 34 (05) :371-382

[5]

Minami Y, 2016, INT J CARDIOVASC IMA

[6]

Oliveira GBF, 2015, FRONT CARDIOVASC MED

[7] Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial [J].

Robinson, Jennifer G. ;

Nedergaard, Bettina S. ;

Rogers, William J. ;

Fialkow, Jonathan ;

Neutel, Joel M. ;

Ramstad, David ;

Somaratne, Ransi ;

Legg, Jason C. ;

Nelson, Patric ;

Scott, Rob ;

Wasserman, Scott M. ;

Weiss, Robert .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (18) :1870-1882

[8] Ectopic adiposopathy and association with cardiovascular disease risk factors: The Uberlandia Heart Study [J].

Roever, L. ;

Resende, E. S. ;

Diniz, A. L. D. ;

Penha-Silva, N. ;

Veloso, F. C. ;

Casella-Filho, A. ;

Dourado, P. M. M. ;

Chagas, A. C. P. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 190 :140-142

[9] Perirenal Fat and Association With Metabolic Risk Factors The Uberlandia Heart Study [J].

Roever, Leonardo ;

Resende, Elmiro S. ;

Veloso, Fernando C. ;

Diniz, Angelica L. D. ;

Penha-Silva, Nilson ;

Casella-Filho, Antonio ;

Dourado, Paulo M. M. ;

Chagas, Antonio C. P. .

MEDICINE, 2015, 94 (38)

[10] Prevalence of Sleep Disordered Breathing Symptoms and Risk Factors for Chronic Diseases: Are There Differences in Countries of High and Low Income? [J].

Roever, Leonardo ;

Quan, Stuart F. .

SLEEP, 2015, 38 (09) :1349-1350

← 1 2 →